Guardian Bio

Dendritic cell-based platform for cancer therapy

Guardian Bio operates in healthcare based in Boston, MA, USA.

Profile

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies.

Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body.

Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

As a business in healthcare, Guardian Bio is listed here with the public details available about it.

Boston, MA, USA is where the company is located.

The company is listed at the Summer 2022 stage of development.

The company reports a headcount in the 2 range.

Website: www.guardian-bio.com